Next 10 |
CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, to...
ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 17, 2024) - Faruqi & Faruqi, LLP, a leading national se...
SAN FRANCISCO, March 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now . Class Period: Aug. 5, 2021 – Nov. 29, 2023 Lead Plaintiff Deadline: Mar. 19, 2024 Visit: ww...
Philadelphia, Pennsylvania--(Newsfile Corp. - March 13, 2024) - A securities fraud lawsuit has been filed against BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI). The lawsuit is captioned Olmstead v. BioVie Inc. et al. , No. 3:24-cv-00035 (D. Nev.), and is filed on behalf of purchasers of...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 11, 2024) - Faruqi & Faruqi, LLP, a leading national se...
Recently completed financing provides sufficient funds for near-term Parkinson’s Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson’s Disease being finalized with targeted launch late-summer 2024 Once-daily NE3107 formulatio...
CARSON CITY, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-dege...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 61.6% to $0.143 on volume of 387,468,585 shares Fisker Inc. Class A (FSR) fell 8.5% to $0.4415 on volume of 205,557,321 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 3.0% to $3.22 on vol...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 58.0% to $0.1398 on volume of 323,150,710 shares Fisker Inc. Class A (FSR) fell 6.7% to $0.45 on volume of 175,737,100 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.2% to $3.115 on vol...
News, Short Squeeze, Breakout and More Instantly...
BioVie Inc. Company Name:
BIVI Stock Symbol:
OTCMKTS Market:
CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, to...
ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern ...
SAN FRANCISCO, March 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now . Class Period: Aug. 5, 2021 – Nov. 29, 2023 Lead Plaintiff Deadline: Mar. 19, 2024 Visit: ww...